[3H]Quinuclidinyl benzilate binding to rat brain muscarinic receptors decreased after repeated exposure to soman, a potent organophosphorus cholinesterase inhibitor.
Abstract
[3H]Quinuclidinyl benzilate binding to rat brain muscarinic receptors decreased after repeated exposure to soman, a potent organophosphorus cholinesterase inhibitor.
The topographical distribution of this decrement was analyzed by quantitative receptor autoradiography. After 4 weeks of soman, three times a week, quinuclidinyl benzilate binding decreased to 67 to 80% of control in frontal and parietal cortex, caudate-putamen, lateral septum, hippocampal body, dentate gyrus, superior colliculus, nucleus of the fifth nerve, and central grey. Minor or no decreases were observed in thalamic or hypothalamic nuclei, reticular formation, pontine nuclei, inferior colliculus, nucleus of the seventh nerve, and cerebellum. Scatchard analyses of saturation curves using frontal cortex sections from soman-treated rats revealed a decrease in maximal quinuclidinyl benzilate binding from that in control rats and a return toward control levels by 24 days without any significant change in affinity. These brain areas showing significant decrements in muscarinic receptors recovered with a similar time course. An estimate of the time for 50% recovery for some of the brain areas was 14 days for superior colliculus, 16 days for cortex, and 19 days for hippocampal body. The application of quantitative receptor autoradiography to analyze receptor alterations has been valuable in localizing the telencephalon as a region more susceptible to change in receptor concentration.
Soman
(0,1,2,2-trimethylpropyl methylphosphonofluoridate) is a potent irreversible inhibitor of cholinesterase which has pronounced central actions. Single, near-lethal doses of soman in rats induced intense generalized convulsions and a marked activation of the brain as assessed by 2-deoxyglucose utilization (McDonough et al., 1983a) . These effects have been attributed to a rapid accumulation of excess acetylcholine in brain (Michaelis et al., 1954; Fonnum and Gottormsen, 1969; Milosevic, 1970; Shih, 1982) inhibitors produces a decrease in the concentration of muscarinic receptors (Ehlert and Kokka, 1977; Schiller, 1979; Uchida et al., 1979; Ehlert et al., 1980a, b; Schwab et al., 1981; Costa et al., 1981 Costa et al., , 1982 Yamada et al., 1983) . Adaptive changes, such as down-regulation of muscarinic receptors, occur as a consequence of persistent cholinomimetic activity. The overall effect of repeated exposure to these agents is dependent on the cumulative effect on cholinesterase levels and the ability to adapt to these low cholinesterase levels. Computer-assisted quantitative autoradiography is a valuable tool for determining both the neuroanatomical localization and concentration of receptors in specific brain regions Rainbow et al., 1982; Unnerstall et al., 1982) . Alterations in receptor concentration have been analyzed for specific brain regions using this technique on brains from lesioned animals (Palacios and Kuhar, 1981; Penney et al., 1981; Pan et al., 1983 (Kuhar and Yamamura, 1975; Rotter et al., 1979) . Using [3H]QNB, we (Churchill et al., 1984) have shown that muscarinic receptor autoradiography is effective for quantitating the topographical distribution of decrements in muscarinic receptors after repeated exposure to diisopropyl fluorophosphate (DFP). (Davies, 1961) .
Results
Quantitation of QNB binding by muscarinic receptor autoradiography. The autoradiogram density for the frontal cortex previously incubated in a range of QNB concentrations and the radioactivity in frontal cortex scraped from the same sections were quantified and compared. For the narrow range of film densities and radioactivities calculated with these QNB concentrations, an approximate linear relationship was found between the picomoles of QNB bound per milligram of tissue and the film density after a &day film exposure ( (Fig. 3, A to C) . Decrements in binding appeared in telencephalic regions-cortex, caudate-putamen, hippocampal body, and dentate gyrus (Fig. 3, A and B) . Repeated soman exposure uniformly reduced muscarinic receptors in the outside (layers I to IV) and inside (layer VI) bands of cortex. Reductions in QNB binding appeared uniformly over the subiculum, regio superior, regio inferior, area dentata, and hilus. Autoradiographic densities were high over the caudate-putamen (Fig. 3 , Aa and Ab) except where the fiber bundles of the internal capsule passed through and minor decreases were observed after soman exposure. Decrements in binding were also observed in the piriform cortex (Fig. 3 , Aa and Ab), amygdala, and septum (Fig. 3Ab) . The corpus callosum, internal capsule, alveus, and globus pallidus (Fig. 3, A and B) were unlabeled in these autoradiograms.
Although regions of the diencephalon, such as thalamus and hypothalamus, showed some differentiation into specific areas within the muscarinic receptor autoradiogram, no decrements in receptor density appeared in brains from the soman-treated rats (Fig. 3 , Ad and Ba to Bc). Higher densities of muscarinic receptors highlighted the anteroventral thalamus (Fig. 3Ad ), but QNB binding did not decrease in soman-treated rats. In the mesencephalic regions, QNB binding decreased in the superior colliculus, mainly in the superficial grey layer (Fig. 3 , Bd, Ca and Cb) and in the central grey (Fig. 3, Bd and Ca) . QNB binding to the inferior colliculus was similar in control and soman-treated rats (Fig. 3Cc ). In the metencephalic regions, decreases in QNB binding in motor trigeminal nucleus (fifth) were observed (Fig. 3Ca) but not in the nucleus of the facial nerve (seventh) (Fig. 3Cb) . No decreases in QNB binding to reticular formation or pontine nuclei were observed (Fig. 3 , Bb to Bd).
In the myelencephalon, the hypoglossal nuclei and nucleus tractus solitarius had higher QNB binding than adjacent regions without showing any differences between control and soman-treated rats (Fig. 3Cd) . The cerebellum was very low in QNB binding and similar between controls and experimental rats (Fig. 3Cd) .
Recovery of muscarinic receptor binding. By analyzing the same brain section from rats sacrificed at different times after the last soman injection, the time course of recovery can be analyzed. Initially, at 1 hr and 24 hr after soman exposure was stopped, the [3H]QNB binding was decreased in hippocampal body, cortex, superior colliculus, and central grey (Fig. 4) . Gradually, the [3H]QNB binding increased in these brain regions, approaching control values by 12 to 24 days. Quantitation of the decrements and recovery of muscarinic receptors. Quantitation of the film densities of selected brain regions within muscarinic receptor autoradiograms from rats sacrificed 24 hr after the last injection revealed decreases in frontal cortex (layers I to IV and VI), caudate-putamen, lateral septum, parietal cortex (I to IV and VI), hippocampal body, dentate gyrus (hilus and molecular layer), superior colliculus, central grey, and motor trigeminal nucleus (fifth) of somantreated rats relative to controls (Table I ). In general, the optical densities of these brain regions in soman-treated rats were 67 to 80% of control. The Student's t test demonstrated that these differences were significant at p < 0.05. No significant differences were observed in the thalamic nuclei (anteroventral, ventrolateral, or medial geniculate), hypothalamic nuclei (dorsal medial), reticular formation, pontine nuclei, inferior colliculus, the nucleus of the seventh (facial) nerve, or cerebellum.
Analysis of the time course of recovery in brain regions where significant decreases occurred at 24 hr indicated a similar time course of recovery for the different brain areas (Fig. 5) . Recovery appeared to be linear; therefore, as an estimate of recovery we analyzed the recovery data by linear regression. Linear regression analyses revealed similar rates of recovery for the examples selected: superior colliculus (0.000253 pmol/mg of tissue/hr) and frontal and parietal cortex (0.000261 pmol/mg of tissue/hr) and a slightly slower rate of recovery for the hippocampal body (0.000242 pmol/mg of tissue/hr). These slopes were not statistically different from each other. The time for 50% recovery was 14 days for superior colliculus, 16 days for cortex, and 19 days for hippocampal body. The rates of recovery are within a similar range for all of the brain regions analyzed.
Saturation and Scatchard analyses of muxarinic receptor binding in soman-treated rats. Saturation curves of [3H]QNB binding (0.125 to 2.0 nM) and Scatchard analyses of this data in the frontal cortex of rats revealed a decrease in maximal binding 24 hr after the last injection (Fig. 6) . The linear plot of the Scatchard analyses of the control data yields a Kn of 0.73 nM and a B,,, of 1.02 pmol/mg of tissue, whereas the Caudate-putamen, lateral septum, and frontal cortex were measured in Figure 3Ab ; dentate gyms, hippocampal body, parietal cortex, central grey, and superior colliculus were measured in Figure 3Bd . Brains from four to six rats were analyzed for both soman-treated (24 hr after last injection) and controls. (Fig. 6, inset) . No statistical differences were found between the slopes of these linear regressions.
The decrease in maximal binding in the soman-treated rats was 66.7% of control. Therefore, soman exposure appears to decrease the maximal binding without significantly affecting the affinity. By 24 days after the last injection, the maximal binding of QNB approached control levels, as evidenced by a B,,, of 0.94 pmol/mg of tissue and a KD of 0.66 nM.
Discussion
Repeated exposure to soman decreased the concentration of muscarinic receptors in many brain regions but not all, as assessed by quantitative receptor autoradiography. In those brain areas with significant decrements in [3H]QNB binding, recovery to near normal values occurred by 24 days post-soman treatment.
Scatchard analyses of saturation curves for [3H] QNB binding to frontal cortex (see Fig. 6 ) revealed a significant decrease in maximal binding (B,,,) for the group analyzed 24 hr post-soman treatment, whereas the B,,,for the 24-day postsoman treatment group was not significantly different from control. The affinity (KD) was similar in all groups. Similar changes in QNB binding kinetics have been reported for repeated exposures to other anticholinesterase agents (Schiller, 1979; Ehlert et al., 1980a, b; Costa et al., 1981; Schwab et al., 1981; Yamada et al., 1983) . These observations suggest that synaptic transmitter concentration may modulate the sensitivity of postsynaptic receptors (Bito and Dawson, 1970) , perhaps through increased endocytosis and degradation of receptors (Klein et al., 1979) .
Computer-assisted densitometric analysis of autoradiograms was used to assess ["HI QNB binding to specific brain areas. To determine the relationship between film density and picomoles of [3H]QNB bound, we used saturation curves generated by exposing frontal coronal brain sections to a range of [3H]QNB mean f SEM (N) mean + SEM (N) concentrations and by quantitating the film density and radioactivity in the frontal cortex from the same sections. The relationship between film density and [3H]QNB bound was approximately linear within the range of radioactivity and film density used in these experiments. This method of standardization is different from the use of soluble radioactive ligand in brain pastes as standards Unnerstall et al., 1982) and has the distinct advantage that the distribution of radioactivity per brain area is similar in standards and unknowns.
Films were also exposed to ['*C]methyl methacrylate standards along with the brain sections to adjust for differences in film exposure or development.
When [3H]QNB bound to frontal cortices scraped from dried sections was compared to that bound to cortical homogenates, the B,,, was 3-fold higher for sections than homogenates. The greater binding of ["H]QNB to coronal sections than to homogenates may be a result of damage to binding sites during homogenization and sonication, possibly by enhanced protease activity.
Decrements in muscarinic receptors as assessed by [3H]QNB binding were observed in specific brain areas 24 hr after repeated exposure to soman. These decrements were not uniform throughout the brain. Most of the brain regions that showed significant decrements in QNB binding were in the telencephalon. The greatest decrements occurred in the telencephalic areas of cortex and hippocampus.
One reason for this differential response might be the substantially longer duration of the ACh elevation in cortex and hippocampus than in brain stem or midbrain following a 0.9 LDbO dose of soman (Shih, 1982) . The topographical distribution of decrements in [3H] QNB binding was similar to that found after repeated exposure to DFP (Churchill et al., 1984 quantitative decreases of 70 to 80% of control were obtained when [3H]QNB binding to dissected brain homogenates was determined after repeated exposure to other anticholinesterase agents (Gazit et al., 1979; Ehlert et al., 1980a, b; Costa et al., 1981; Schwab et al., 1981; Yamada et al., 1983) .
In general, regional decreases in [3H]QNB binding induced by multiple exposures to anticholinesterase agents were similar among the different anticholinesterase agents; however, there were a few notable differences. For example, in the pontine nuclei, a significant decrement (67% of control) occurred after repeated DFP exposure (Churchill et al., 1984) , whereas no significant decreases occurred after repeated soman exposure. Likewise, Gazit et al. (1979) noted a decrease in [3H]QNB binding in the thalamus after exposure to Tetram, whereas no changes were detected in the thalamic areas after soman or DFP exposure (Yamada et al., 1983; Churchill et al., 1984) .
Similarities in decrements of muscarinic receptors induced by soman or DFP exposure are in striking contrast to the behavioral and brain regional glucose use changes caused by single, near-lethal doses of these two agents. Soman at nearlethal doses induced strong persistent seizures in rats (McDonough et al., 1983a) , whereas DFP only produced peripheral cholinomimetic effects with brief convulsant-like activity occurring just prior to death. Associated with the intense seizure activity induced by soman was a marked elevation of local cerebral glucose utilization in many brain regions as assessed by the 2-deoxyglucose technique (McDonough et al., 1983a) . On the other hand, DFP had a minimal impact on local cerebral glucose utilization in the brain except for retinal-mediated activation of the superficial layer of the superior colliculus (Nelson et al., 1978; Pazdernik et al., 1982) . The similarity in muscarinic receptor down-regulation, in contrast to the major differences between these two agents on glucose utilization in the brain, suggests that soman-induced seizures may be in part dependent on noncholinergic processes (O'Neill, 1981; Samson et al., 1984) .
Conspicuous neuropathology was observed in the piriform cortex of 5 of 36 experimental rats during inspection of the receptor autoradiograms (Churchill et al., 1983) . Extensive cell loss and tissue fragmentation in the piriform cortex were confirmed by hematoxylin and eosin staining of adjacent sections. McLeod et al. (1984) and Lemercier et al. (1983) also reported extensive neuropathology in the piriform cortex in all rats that had intense soman-induced seizures.
[3H]QNB binding in the piriform cortex of these five experimental rats was extremely low (45.4 f 7.8% of control), whereas [3H]QNB binding to frontal cortex and other telencephalic brain regions in these five rats was similar to that observed in brains from rats without notable pathology. This gross irreversible pathology in selected brain regions of some rats exposed to soman suggests that inferences about mechanisms underlying the changes in [3H] QNB binding after soman exposure should be made cautiously. For example, the decrements in QNB binding might be the exposure. The time course of recovery for muscarinic receptors was compared to that for brain cholinesterase activity after soman exposure in a parallel study (McDonough et al., 1983b) . A half-life of recovery for brain cholinesterase activity was 8 to 11 days in midbrain, hippocampus, and cortex. A slightly earlier recovery of brain cholinesterase activity than of ["HIQNB binding suggests that these two events may be linked.
